WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
PATENTSCOPE will be unavailable a few hours for maintenance reason on Saturday 18.08.2018 at 9:00 AM CEST
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2017062694) COMPOSITIONS AND METHODS OF TREATING SKIN FIBROTIC DISORDERS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2017/062694 International Application No.: PCT/US2016/055865
Publication Date: 13.04.2017 International Filing Date: 07.10.2016
IPC:
A61P 35/00 (2006.01) ,A61K 31/505 (2006.01) ,A61K 31/506 (2006.01) ,A61K 31/517 (2006.01) ,A61K 45/00 (2006.01)
Applicants: TANG-LIU, Diane[US/US]; US
LIU, Tiffany[US/US]; US
Inventors: TANG-LIU, Diane; US
LIU, Tiffany; US
Agent: LIANG, T. Chyau; US
Priority Data:
62/238,30907.10.2015US
Title (EN) COMPOSITIONS AND METHODS OF TREATING SKIN FIBROTIC DISORDERS
(FR) COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE TROUBLES FIBREUX DE LA PEAU
Abstract: front page image
(EN) A method for preventing and/or modulating formation of a dermal fibrotic disorder includes administering a therapeutically effective amount of a multi-phase modulator to a subject in need thereof. The multi-phase modulator is selected from the group consisting of axitinib, nintedanib, sorafenib, sunitinib, lenvatinib, panatinib, pazopanib, regorafenib, and riociguat. The dermal fibrotic disorder is acne scars, skin scars such as keloids and hypertrophic scars, wrinkles, cellulite and dermal neoplastic fibrosis, scarring alopecia, various vasculopathy, vasculitis, burn wound healing, diabetic foot syndrome, scleroderma, arthrofibrosis, Peyronie's disease, dupuytren's contracture, or adhesive capsulitis
(FR) L'invention concerne un procédé permettant de prévenir et/ou de moduler la formation d'un trouble fribeux cutané qui consiste à administrer, à un sujet en ayant besoin, une quantité thérapeutiquement efficace d'un modulateur multiphase. Le modulateur multi-phase est choisi dans le groupe constitué par l'axitinib, le nintédanib, le sorafénib, le sunitinib, le lenvatinib, le panatinib, le pazopanib, le régorafénib, et le riociguat. Ledit trouble fibreux cutané étant des cicatrices d'acné, des cicatrices de la peau telles que des chéloïdes et des cicatrices hypertrophiques, des rides, la cellulite et la fibrose néoplasique cutanée, la formation de cicatrices liées à l'alopécie, diverses vasculopathies, la vascularite, la cicatrisation de brûlure, le syndrome du pied diabétique, la sclérodermie, l'arthrofibrose, la maladie de la Peyronie, la maladie de Dupuytren, ou la capsulite rétractile.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)